Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process, three sources close to the sale told Reuters. Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle-based Dendreon, best known for its Provenge cancer treatment.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 2.57% or $4.12/share to $164.22. In the past year, the shares have traded as low as $106.00 and as high as $165.69. On average, 2114130 shares of VRX exchange hands on a given day and today's volume is recorded at 1666413.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 3.73% or $7.44/share to $206.81. In the past year, the shares have traded as low as $116.01 and as high as $205.98. On average, 432892 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 669732.
Source
